<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="630">
  <stage>Registered</stage>
  <submitdate>13/09/2005</submitdate>
  <approvaldate>12/10/2005</approvaldate>
  <actrnumber>ACTRN12605000631606</actrnumber>
  <trial_identification>
    <studytitle>Treatment of acute exacerbations of asthma in children with a doubling of the usual inhaled corticosteroid (ICS) dose.</studytitle>
    <scientifictitle>A Multicentre Randomised Controlled Trial of Treatment of Acute Exacerbations of Asthma in Children with a Doubling of the Usual Inhaled Corticosteroid(ICS) Dose to identify efficacy of intervention.</scientifictitle>
    <utrn />
    <trialacronym>DICS Study</trialacronym>
    <secondaryid>FMS40267</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Asthma</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Asthma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Double blind, placebo-controlled, parallel, multi-centre trial.  Children will be regularly on inhaled Fluticasone Propionate.  Children will be randomised to receive either double their usual dose of inhaled corticosteroids or their usual dose of inhaled corticosteroid + placebo with intercurrent upper respiratory infections or exacerbations of their asthma for the following 12 months.

Children aged 6 years or older will be asked to perform spirometry at all visits.  Peak flow measurements will also be recorded.  Height and weight will be measured using standard equipment (Harpenden stadiometer or equivalent) that will be consistent for each centre at each visit.</interventions>
    <comparator>Placebo</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine whether doubling inhaled corticosteroids at the first sign of a cold or of asthma deterioration in children on preventive treatment with inhaled corticosteroids leads to a reduced need for oral steroid rescue or reduced risk of admission to hospital.</outcome>
      <timepoint>At the time of admission</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Time for peak flow values and spirometry to return to baseline in children old enough to perform lung function</outcome>
      <timepoint>at the first sign of a cold or of asthma deterioration </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>School days missed in school aged children.</outcome>
      <timepoint>at the first sign of a cold or of asthma deterioration </timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Currently using 125mcg or greater of inhaled Cortico-steroid dailyExacerbation of asthma in past 12/12 requiring Oral Steroid</inclusivecriteria>
    <inclusiveminage>3</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>14</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Children with other respiratory diseases such as cystic fibrosis. Children with other significant medical conditions that may affect growth.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>The randomisation key is concealed and held at the Department Epidemiology and Preventative Medicine (DEPM), Monash Medical School, Melbourne. Central randomisation by phone/fax occurred after consent was obtained.</concealment>
    <sequence>We use stratified blocked randomisation of subjects to Active or Control groups using Stata (1,2); stratification was by site, sex, and age group, and blocks were used.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>24/07/2002</anticipatedstartdate>
    <actualstartdate>5/05/2002</actualstartdate>
    <anticipatedenddate />
    <actualenddate>21/11/2003</actualenddate>
    <samplesize>250</samplesize>
    <actualsamplesize>250</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Asthma Foundation Queensland</primarysponsorname>
    <primarysponsoraddress>42 Costin Street, Fortitude Valley 4006</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Asthma Foundation Queensland</fundingname>
      <fundingaddress>42 Costin Street, Fortitude Valley 4006</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Infrastructure Funding from RCH Foundation</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress>Nil</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To determine whether doubling inhaled corticosteroids at the first sign of a cold or of asthma deterioration in children on preventive treatment with inhaled corticosteroids leads to a reduced need for oral steroid rescue or reduced risk of admission to hospital.
To examine the effect of doubling the dose of inhaled corticosteroids at the first sign of a cold or asthma deterioration on the growth of children on preventive treatment for asthma.

</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Children's Hospital &amp; Health Service District </ethicname>
      <ethicaddress>Herston Rd
Herston 4029</ethicaddress>
      <ethicapprovaldate>29/10/2001</ethicapprovaldate>
      <hrec>DICS Study</hrec>
      <ethicsubmitdate>16/09/2003</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>West Moreton Health Service District</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Gold Coast Health Service District</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Bayside Health Service District</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Wesley Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Claire Wainwright</name>
      <address>5a Respiratory &amp; Sleep Medicine
Lady Cilento Children's Hospital
501 Stanley St.
South Brisbane</address>
      <phone>+617 30681111</phone>
      <fax>+617 30697159</fax>
      <email>claire.wainwright@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Claire Wainwright</name>
      <address>5a Respiratory &amp; Sleep Medicine
Lady Cilento Children's Hospital
501 Stanley St.
South Brisbane</address>
      <phone>+617 30681111</phone>
      <fax>+617 30697159</fax>
      <email>claire.wainwright@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Claire Wainwright</name>
      <address>5a Respiratory &amp; Sleep Medicine
Lady Cilento Children's Hospital
501 Stanley St.
South Brisbane</address>
      <phone>+617 30681111</phone>
      <fax>+617 30697159</fax>
      <email>claire.wainwright@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Claire Wainwright</name>
      <address>5a Respiratory &amp; Sleep Medicine
Lady Cilento Children's Hospital
501 Stanley St.
South Brisbane</address>
      <phone>+617 30681111</phone>
      <fax>+30697159</fax>
      <email>Claire Wainwright</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>